[EN] THERAPEUTIC BORON-CONTAINING COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES CONTENANT DU BORE
申请人:UNIV TROMSOE
公开号:WO2013104897A1
公开(公告)日:2013-07-18
The present invention relates to compounds of Formula (I) wherein R1 and R3 are hydrogen; R2 and R4, which may be the same or different, are hydrogen, a C1-6 alkyl group optionally substituted by an aryl group which may itself be substituted, the substituent group including an alkyl group or an -OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; or an aryl group which may be substituted, the substituent group including an alkyl group or an -OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; with the proviso that R2 and R4 are not both hydrogen; the atom of R4 which is attached to Cβ is either a saturated carbon atom or an atom which is part of a 1 substituted aromatic ring; (AA)0-5 is an amino acid, amino acid derivative, peptide of up to 5 amino acids or a peptidomimetic thereof which optionally incorporates an N-terminal capping group, when the group is (AA)0 an N-terminal capping group is present, covalently attached to the nitrogen atom shown in Formula (I) and the capping group comprises at least 5 non-hydrogen atoms; R5 is hydrogen or a C1-3 20 alkyl group, when AA=0, R5 may form a cyclic group with the N-terminal capping group; R6 and R7 independently of one another denote hydrogen or a C1-6 alkyl group; or together with the boron atom and the oxygen atoms, form a mono-, bi- or tricyclic, saturated or partly unsaturated, mono-, di-, tri- or tetra- C1-6 alkylated or phenylated ring system having 5-18 ring members; and salt forms and stereoisomers thereof. The invention further relates to pharmaceutical formulations containing these compounds and the use of these compounds in therapy, particularly as antimicrobial agents, more particularly as an agent effective in treating a Mycobacterium tuberculosis infection or a Candida albicans infection. (I)
本发明涉及式(I)的化合物,其中R1和R3为氢;R2和R4,可以相同也可以不同,为氢,一个C1-6烷基基团,可选择地被芳基基团取代,该芳基基团本身可能被取代,取代基团包括一个烷基基团或一个-OR基团,其中R为C1-3烷基基团,其中一个或多个氢原子可选择地被卤素原子取代;或者为一个可能被取代的芳基基团,取代基团包括一个烷基基团或一个-OR基团,其中R为C1-3烷基基团,其中一个或多个氢原子可选择地被卤素原子取代;但R2和R4不能同时为氢;与连接到Cβ的R4原子是饱和碳原子或是1-取代芳香环的一部分的原子;(AA)0-5是氨基酸、氨基酸衍生物、最多含有5个氨基酸的肽或其肽类似物,可选择地包含一个N-末端帽基团,当该基团为(AA)0时,存在一个N-末端帽基团,共价连接到式(I)中所示的氮原子,并且帽基团至少包含5个非氢原子;R5为氢或C1-3烷基基团,当AA=0时,R5可以与N-末端帽基团形成一个环状基团;R6和R7彼此独立地表示氢或C1-6烷基基团;或者与硼原子和氧原子一起形成一个单环、双环或三环的饱和或部分不饱和的、单烷基化或苯基化的环系统,具有5-18个环成员;以及其盐形式和立体异构体。本发明还涉及含有这些化合物的药物配方以及这些化合物在治疗中的使用,特别是作为抗微生物药物,更具体地作为一种有效治疗结核分枝杆菌感染或念珠菌感染的药物。